1.14.11.51: DNA N6-methyladenine demethylase
This is an abbreviated version!
For detailed information about DNA N6-methyladenine demethylase, go to the full flat file.
Word Map on EC 1.14.11.51
-
1.14.11.51
-
dioxygenase
-
demethylation
-
histone
-
2-oxoglutarate-dependent
-
abasic
-
alkbh7
-
eraser
- 1.14.11.51
- dioxygenase
-
demethylation
- histone
-
2-oxoglutarate-dependent
-
abasic
-
alkbh7
-
eraser
Reaction
Synonyms
6mA DNA demethylase, ALKBH1, DMAD, DNA 6mA demethylase, NMAD, NMAD-1
ECTree
Advanced search results
Application
Application on EC 1.14.11.51 - DNA N6-methyladenine demethylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
development of assay method using a methylation-sensitive restriction endonuclease
medicine
ALKBH1 overexpression decreases hepatocellular carcinoma cell viability, induces apoptosis, and decreases migration and invasion. 23779 gain-of-6 mA regions and 11240 loss-of-6 mA regions are differentially identified in hepatocellular carcinoma tissues. The differential gain and loss of 6 mA regions are considerably enriched in intergenic regions. 7% of the differential 6 mA modifications are associated with tumors, with 60 associated with oncogenes and 57 with tumor suppressor genes, and 17 are common to oncogenes and TSGs
medicine
during the progression of vascular calcification in a model of chronic kidney disease, increased ALKBH1 expression is linked to decreased 6mA levels
medicine
expression levels of ALKBH1 in lung cancer tissues and cells are up regulated. The invasion and migration abilities of lung cancer cells are significantly suppressed in vitro upon the silencing of ALKBH1 while they are significantly promoted upon its overexpression
medicine
in patients with chronic kidney disease, leukocyte 6mA levels are significantly reduced as the severity of vascular calcification increases. Decreased 6mA demethylation results from the upregulation of ALKBH1. ALKBH1 overexpression aggravates whereas its depletion blunts vascular calcification progression and osteogenic reprogramming in vivo and in vitro